Transition Bio

aid: transition-bio
name: Transition Bio
description: 'Transition Bio is a preclinical drug discovery company built on biomolecular condensate science, operating as
  a joint spin-out of the University of Cambridge and Harvard University with sites in Cambridge, Massachusetts and Cambridge,
  United Kingdom. The company combines droplet-microfluidics high-throughput molecular screening with a machine learning engine
  to identify and optimize small molecules that modulate intrinsically disordered proteins and the condensates they form,
  an approach the company has described as its Condensomics platform. It was seeded in November 2020 and closed a $50 million
  Series A in June 2022 led by Northpond Ventures with Taiho Ventures, Bristol Myers Squibb and Magnetic Ventures participating,
  and in November 2025 announced a collaboration with Voyager Therapeutics on small molecules targeting TDP-43 in ALS and
  frontotemporal dementia. Transition Bio is a therapeutics developer rather than a software or data vendor: it publishes
  no developer portal, no API documentation and no machine-readable API contract on any host it controls.'
url: https://raw.githubusercontent.com/api-evangelist/transition-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
specificationVersion: '0.20'
created: '2026-08-30'
modified: '2026-08-30'
image: https://transitionbio.com/wp-content/uploads/2022/04/logo.png
tags:
- Company
- Biotechnology
- Drug Discovery
- Life Sciences
- Machine-Learning
- Artificial Intelligence
- Microfluidics
- Proteomics
- Therapeutics
- Neurodegeneration
tags_raw:
- Company
- Biotechnology
- Drug Discovery
- Life Sciences
- Machine Learning
- Artificial Intelligence
- Microfluidics
- Proteomics
- Therapeutics
- Neurodegeneration
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://transitionbio.com/
- type: About
  url: https://transitionbio.com/about-us/
- type: Blog
  url: https://transitionbio.com/news/
- type: BlogRSS
  url: https://transitionbio.com/feed/
- type: Support
  url: https://transitionbio.com/contact-us/
- type: GitHubOrganization
  url: https://github.com/transitionbio
- type: LinkedIn
  url: https://www.linkedin.com/company/transition-bio-inc/
- type: Careers
  url: https://transitionbio.com/careers/
- type: Partners
  url: https://transitionbio.com/collaborate/
- type: LLMsTxt
  url: llms/transition-bio-llms.txt
- type: DomainSecurity
  url: security/transition-bio-domain-security.yml
x-enrichment:
  date: '2026-08-30'
  status: minimal
  artifacts_added: 4
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Transition Bio is a preclinical therapeutics developer whose product is drug candidates, not software; its entire
    web presence is an 11-page WordPress marketing site with no developer section, and every contract-discovery path (/openapi.json,
    /swagger.json, /api-docs, /graphql, /llms.txt and all seven /.well-known/ paths) returned 404, while api./docs./developer.
    transitionbio.com are wildcard DNS to the same shared host serving that marketing site.
  evidence:
  - url: https://transitionbio.com/openapi.json
    status: 404
  - url: https://transitionbio.com/swagger.json
    status: 404
  - url: https://transitionbio.com/api-docs
    status: 404
  - url: https://transitionbio.com/graphql
    status: 404
  - url: https://transitionbio.com/llms.txt
    status: 404
  - url: https://transitionbio.com/.well-known/agent-card.json
    status: 404
  - url: https://transitionbio.com/.well-known/api-catalog
    status: 404
  - url: https://transitionbio.com/
    status: 200
  checked: '2026-08-30'